AC2993 + AC2993 + Placebo + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Non-Insulin-Dependent
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Trial Timeline
Feb 1, 2002 → Aug 1, 2003
NCT ID
NCT00039026About AC2993 + AC2993 + Placebo + Placebo
AC2993 + AC2993 + Placebo + Placebo is a phase 3 stage product being developed by AstraZeneca for Diabetes Mellitus, Non-Insulin-Dependent. The current trial status is completed. This product is registered under clinical trial identifier NCT00039026. Target conditions include Diabetes Mellitus, Non-Insulin-Dependent.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00035984 | Phase 3 | Completed |
| NCT00039013 | Phase 3 | Completed |
| NCT00039026 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Non-Insulin-Dependent